Regulatory filing 📈 Stocks 🌍 Hong Kong

China Tian Yuan Healthcare Faces Trading Suspension Over Rule 13.24 Breach

China Tian Yuan Healthcare Group faces a trading suspension after the Stock Exchange ruled its operations and assets are insufficient to warrant continued listing, citing a revenue collapse from HK$94.6 million in 2021 to HK$19.8 million in 2025.

🕐 1 min read 📰 HKEX

1 assets impacted. Net bias: 0 Bullish, 1 Bearish, 0 Neutral. Strongest signal: 0557.HK ↓ 8/10 (90% confidence).

📊 Affected Assets (1)

0557.HK
Bearish 🤖 90%
📅 Short-term 🌍 HK · Explicit

On 20 November 2026 the Stock Exchange decided the Company failed to maintain sufficient operations and assets under Rule 13.24, and trading in its shares (Stock Code 557) will be suspended under Rule 6.01(3). A suspension plus delisting risk is a direct, severe negative for the stock, compounded by revenue collapsing from HK$94.6 million in 2021 to HK$19.8 million in 2025 with net losses every year. Nothing in the letter mitigates the decision.

Catalysts
  • ▼ Exchange letter dated 20 November 2026 ordering trading suspension under Rule 6.01(3)
  • ▼ Revenue decline from HK$94.6 million (2021) to HK$19.8 million (2025) with net losses in all five years
Risk Factors
  • ▲ Trading suspension blocks existing holders from selling shares
  • ▲ Remaining businesses judged small, not viable or sustainable

🎯 Key Takeaways

  • Revenue declined from HK$94.6 million in 2021 to HK$19.8 million in 2025, with net losses recorded in each of the five years.
  • The Stock Exchange ordered a trading suspension under Rule 6.01(3) effective 2 December 2026.
  • The company has until 1 December 2026 to request a review of the decision by the Listing Committee.
  • As of 30 June 2026, the company reported total assets of HK$243 million and net assets of HK$154 million, with loan receivables comprising a substantial portion.

📝 Executive Summary

The Stock Exchange of Hong Kong has notified China Tian Yuan Healthcare Group Limited that it failed to maintain sufficient operations and assets under Rule 13.24. Consequently, the company faces a trading suspension effective 2 December 2026 unless it requests a review by 1 December 2026.

❓ FAQ

What does this mean for my shares in Tian Yuan Healthcare?

The Stock Exchange has decided the company no longer warrants continued listing under Rule 13.24, and trading in its shares will be suspended under Rule 6.01(3). While suspended, shareholders generally cannot trade the shares until the company resolves the issues or the listing outcome is decided.

Why did the exchange take this action?

The company's revenue fell from HK$94.6 million in 2021 to HK$19.8 million in 2025 with net losses every year; it stopped its plastic surgery and light medical beauty businesses, and its remaining trademark licensing, skincare distribution, money lending, medical examination and health management businesses were all considered too small or unproven to be viable and sustainable.